UK markets open in 5 hours 31 minutes

BNGO Jan 2025 3.000 call

OPR - OPR Delayed price. Currency in USD
Add to watchlist
0.10000.0000 (0.00%)
As of 10:54AM EDT. Market open.
Full screen
Previous close0.1000
Open0.1000
Bid0.0500
Ask0.1000
Strike3.00
Expiry date2025-01-17
Day's range0.1000 - 0.1000
Contract rangeN/A
Volume1
Open interest776
  • GlobeNewswire

    Bionano to Report First Quarter 2024 Financial Results and Host a Conference Call and Webcast on May 8, 2024

    SAN DIEGO, May 01, 2024 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced that it will host a conference call and live webcast on Wednesday, May 8, 2024, at 4:30 p.m. Eastern Time to report financial results for the first quarter 2024 and to highlight recent corporate progress. Conference Call & Webcast Details Date:Wednesday, May 8th, 2024Time:4:30 p.m. ETParticipant Dial-In:Toll Free: 1-833-630-1956International: 1-412-317-1837Webcast Link:https://edge.media-server.com/

  • GlobeNewswire

    Bionano to Present at the RBC Capital Markets 2024 Global Healthcare Conference

    SAN DIEGO, April 30, 2024 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced that Erik Holmlin, PhD, Bionano’s president and chief executive officer, will present at the RBC Capital Markets 2024 Global Healthcare Conference on May 15, 2024. Conference & Webcast Details Date:May 15, 2024Time:8:00 a.m. to 8:25 a.m. ETPresenter:Erik Holmlin, PhD, CEO of BionanoWebcast:Link to Register A replay / recording of the session will be available following the conference through the B

  • GlobeNewswire

    Bionano Announces Publication Showing OGM’s High Resolution Structural Variation Detection in Cancer Validated by Cas9-Directed Nanopore Sequencing

    SAN DIEGO, April 24, 2024 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO), today announced the results of an implementation study conducted by researchers at University Medical Center Groningen that compared optical genome mapping (OGM) to traditional cytogenetic methods for the detection of structural variants (SVs) in bone marrow aspirate (BMA) samples. OGM has been shown to regularly detect SVs missed by other methods, as a result of the higher resolution and sensitivity of OGM. Som